Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FAPI-Guided Hypofractionated Radiotherapy Combined With Cadonilimab and Standard Second-Line Chemotherapy Versus Standard Second-Line Chemotherapy for Peritoneal Metastasis From Colorectal Cancer: A Multicenter, Randomized, Open-Label, Phase III Trial (TORHC-PM02)

NCT07815834 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07815834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07815834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FAPI-Guided Hypofractionated Radiotherapy Combined With Cadonilimab and Standard Second-Line Chemotherapy Versus Standard Second-Line Chemotherapy for Peritoneal Metastasis From Colorectal Cancer: A Multicenter, Randomized, Open-Label, Phase III Trial (TORHC-PM02)
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Recruiting
Start date
October 1, 2026
Completion date
March 1, 2031
Enrollment
198 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon rectal cancer adenocarcinoma, immunotherapy, peritoneal (metastatic) cancer, radiation therapy, second-line treatment